A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Clinical trial NCT03947255 · TERMINATED
Trial details
- NCT number
- NCT03947255
- Sponsor
- Seagen Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-28
- Primary completion
- 2022-11-06
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.